Results 11 to 20 of about 1,844 (180)

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. [PDF]

JACC: Heart Failure
This study was funded by Bristol Myers Squibb, Princeton, New Jersey, USA. Bristol Myers Squibb’s policy on data sharing is available online at https://www.bms.com/researchers-and-partners/clinicaltrials-and-research/disclosure-commitment.html. Dr Rader
Abraham, Theodore P, Balaratnam, Ganesh, Choudhury, Lubna, Fermin, David, Fox, Shawna, Garcia-Pavia, Pablo, Hegde, Sheila M, Masri, Ahmad, Olivotto, Iacopo, Oręziak, Artur, Owens, Anjali, Rader, Florian, Saberi, Sara, Sehnert, Amy J, Seidler, Tim, Wheeler, Matthew T, Zwas, Donna R   +16 more
core   +6 more sources

Transcriptional and functional effects of mavacamten in multiple porcine and human models with hypertrophic cardiomyopathy [PDF]

British Journal of Pharmacology, Volume 183, Issue 5, Page 1122-1139, March 2026.
Background and Purpose: Mavacamten (MAVA) is a novel small molecule inhibitor of cardiac myosin, mitigating cardiomyocyte hypercontractility in patients with hypertrophic obstructive cardiomyopathy (HOCM).
Agyapong, Wilson, Beetz, Oliver, Bentele, Marco, Chatterjee, Shambhabi, Cipriano, Giuseppe, Derda, Anselm A., Gietz, Anika, Haas, Jonas A., Hunkler, Hannah J., Jürgens, Bjarne, Kiselev, Elisa, Liu, Junqing, Menge, Kaja S., Mohr, Elisa, Neumüller, Susanne, Pfanne, Angelika, Pflaum, Michael, Psaras, Yiangos, Salman, Jawad, Sonnenschein, Kristina, Specht, Jonas, Toepfer, Christopher, Waleczek, Florian J. G., Wiegmann, Bettina   +23 more
core   +3 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy. [PDF]

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Savsin H, Tokarek T.
europepmc   +2 more sources

Myosin folding boosts solubility in cardiac muscle sarcomeres [PDF]

JCI Insight
The polymerization of myosin molecules into thick filaments in muscle sarcomeres is essential for cardiac contractility, with the attenuation of interactions between the heads of myosin molecules within the filaments being proposed to result in ...
Colleen M. Kelly, Jody L. Martin, Michael J. Previs   +2 more
doaj   +2 more sources

Case Report: Transient hypertension and myalgia following mavacamten therapy in a patient with hypertrophic obstructive cardiomyopathy. [PDF]

Front Cardiovasc Med
BackgroundMavacamten has been demonstrated to be effective in the treatment of hypertrophic obstructive cardiomyopathy (HOCM). However, its hemodynamic impact and extracardiac effects require further characterization.Case presentationWe report a case of ...
Peng M, Fu Y, Qin C, Zhou S, Sun J.
europepmc   +2 more sources

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Massera D, Adlestein E, Frejat S, Wu WY, Reuter MC, Xia Y, Alvarez IC, Sherrid MV.   +7 more
europepmc   +2 more sources

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy [PDF]

New England Journal of Medicine
Mavacamten is approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). However, its effects in nonobstructive HCM remain uncertain.We conducted a phase 3, international, double-blind, placebo-controlled, clinical trial to ...
Abraham Theodore, Aronson Ron, Azevedo Olga, Carter-Bonanza Suzanne, Desai Milind Y, Elliott Perry, et al., Fernandes Fabio, Florea Victoria, Fogarassy György, Garcia-Pavia Pablo, Gong Zhiqun, Jaber Wael, Kitaoka Hiroaki, Kollaborációs szervezet: ODYSSEY-HCM Investigators, Lopes Renato D, Maier Lars, Meder Benjamin, Merkely Béla Péter, Mitchell Lisa, Myers Jonathan, Nissen Steven E, Olivotto Iacopo, Owens Anjali T, Rano Thomas, Sepp Róbert, Verheyen Nicolas, Wang Qiuqing, Wolski Kathy, Zhong Yue   +29 more
core   +2 more sources

Low-Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real-World Study in China. [PDF]

Cardiovasc Ther
Aims To evaluate the real‐world efficacy and safety of low‐dose (2.5 mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Methods and Results This single‐center observational study (Zhongshan Hospital, China; Oct 2024–Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II/III, LVEF ≥ 55 ...
Yang W, Shi H, Chang RS, Zhang Y, Jixiang A, Wu C, Qian J, Ge J, Zhang S.   +8 more
europepmc   +2 more sources

A New Era in the Management of Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Hypertrophic cardiomyopathy (HCM) is a prevalent cardiac disease characterized by marked phenotypic variability. Recent advances in diagnosis and treatment have allowed a personalized approach to the treatment of this disease.
Perez-Asensio A, Llamas-Gomez H, Lara-Palomo A, Villar-Ruiz A, Jimenez-Mendez C, Palomino-Doza J.   +5 more
europepmc   +3 more sources

Hypertrophic Cardiomyopathy: Current Perspectives. [PDF]

Rev Cardiovasc Med
Hypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Patel D, Bhargav R, Mousa A, Bokhari S.
europepmc   +2 more sources